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Abstract 
Human elongation factor 2 is the translocase that is responsible for the 
movement of tRNA from the A- to P and P- to E-site on the ribosome during the 
elongation phase of translation. Being a vital factor of protein biosynthesis, its 
function is highly controlled and regulated. It has been implicated in numerous 
diseases and pathologies, and as such it is important to have a source for isolated 
pure and active protein for biomedical and biochemical studies. Here we report 
development of a purification protocol for native human elongation factor 2 from 
HEK-293S cells. The resulting protein is active, pure, has an intact diphtamide 
and is obtainable in yields suitable for functional and structural studies.  
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Abbreviations 
eEF2, eukaryotic elongation factor 2; HEK-293F, Human embryonic kidney cells 
293; mRNA, messenger RNA; tRNA, transfer RNA; GMPPCP, Guanosine-5′-[(β,γ)-
methyleno]triphosphate; eEF1A, eukaryotic elongation factor 1A. 
1. Introduction 
Protein biosynthesis is the process whereby the ribosome translates messenger 
RNA (mRNA) into protein. This process is divided into three steps: Initiation, 
Elongation, Termination and Recycling (for recent review see (Dever, Kinzy, and 
Pavitt 2016)). During the initiation phase in eukaryotes a very complex series of 
events finally leads to formation of the 43S pre-initiation complex where 
initiation Met-tRNAi is positioned at the start codon on the mRNA. In the 
elongation step, an aminoacylated tRNA in complex with eukaryotic elongation 
factor 1A (eEF1A) and GTP is brought into the ribosomal A-site depending on the 
codon of the mRNA. The peptidyl transferase reaction then takes place between 
the growing polypeptide carried by the tRNA in the P-site and the amino acid on 
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the tRNA in the A-site. The peptide bond thus formed results in the transfer of 
the growing polypeptide chain to the tRNA in the A-site. Subsequently, GTP-
dependent translocation is catalysed by eukaryotic elongation factor 2 (eEF2) 
and advances the mRNA one codon, moving the peptidyl-tRNA from the A- to the 
P-site, and the deacylated tRNA from the P-site to the E (Exit) site thereby 
vacating the A-site so that it is ready to receive a new aminoacylated tRNA. This 
continues until a stop codon is encountered where release and recycling factors 
dissociate the ribosome and release the nascent polypeptide. 
 
All eEF2 proteins have a uniquely modified histidine residue that has been 
transformed post-translationally into a diphtamide (Van Ness, Howard, and 
Bodley 1980; Collier 2001). This residue is a well-known target for ADP 
ribosylation by several bacterial toxins thereby effectively inactivating the 
translation factor and causing cell death (René Jørgensen et al. 2008; R. 
Jørgensen, Merrill, and Andersen 2006). Although the role of the diphtamide 
modification still remains somewhat elusive, it has been implicated in fidelity of 
translation by prevention of frameshift (Liu et al. 2012). Furthermore, eEF2 
function is highly regulated via phosphorylation by the eEF2K kinase controlled 
via MAP kinase signalling and the mTOR signalling pathway (Kaul, Pattan, and 
Rafeequi 2011).  
 
As eEF2 is one of the most important regulators of the elongation phase of 
protein synthesis, it is not surprising that changes in both its level and activity 
are related to a number of different diseases, including cardiovascular diseases, 
neurological disorders and cancer (Taha et al. 2013; Heise et al. 2014; 
Kameshima et al. 2016). Particularly, eEF2 has been found to be upregulated in 
gastric, breast, lung and prostate cancer (Nakamura et al. 2009; Oji et al. 2014; 
Meric-Bernstam et al. 2012). In addition, eEF2 has been proposed as a potential 
biomarker for the diagnosis of prostate cancer because of its high correlation 
with circulating prostate-specific antigen (PSA), one the most recognized clinical 
factors used to identify the best treatment regime in prostate cancer (Zhang et al. 
2017). High expression of eEF2 is also correlated with incidence, recurrence and 
resistance to cisplatin in lung adenocarcinoma (Chen et al. 2011). 
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It is well known that eEF2 functions are mainly regulated by the eEF2 kinase, a 
Ca2+/calmodulin dependent kinase, which is sensitive to nutrient availability and 
to stress affecting cells (Ryazanov et al. 1997; Hizli et al. 2013; Kenney et al. 
2014). Particularly, the PI3K and MAPK pathways are able to inhibit its activity, 
while stress conditions lead to the activation of the kinase through a series of 
activating autophosphorylation events (Pyr Dit Ruys et al. 2012; Kenney et al. 
2014; Kameshima et al. 2016). However to date, the precise mechanism by which 
eEF2 is regulated still remains elusive. For this reason, access to a purified 
human version of eEF2 will be very useful to facilitate biochemical assays that 
will advance our understanding of eEF2 properties and functions. 
 
2. Materials and methods 
2.1 HEK-293 cell production 
HEK-293F cells were cultured in FreeStyle 293 medium (Gibco) until reaching a 
cell density of 0.2x10^6 cells/mL. Cells were then used for recombinant 
expression of secreted proteins for another two to four days.  Subsequently, cells 
were harvested by centrifugation at 220 x g followed by storage of the cell pellets 
at -20°C until further use. 
 
2.2 eEF2 purification 
Approximately 60 g of HEK-293F cell pellet (wet weight) was used per 
purification. Cells were resuspended in buffer L (20 mM Hepes/KOH pH 7.2, 5 
mM MgCl2, 10% v/v glycerol, 0.5% v/v NP-40, 1 mM DTT, one tablet of protease 
inhibitor (Sigma) per 100 mL) using 2 mL per gram of cells. The resuspended 
cells were left on ice for 30 min to complete the detergent-based lysis, followed 
by centrifugation for 30 min, 30000 x g and 4°C to clear lysate. The pH value of 
the cleared lysate was adjusted from 6.2 back to 7.0 using untitrated 1 M Tris 
base and diluted with one volume buffer S (20 mM Hepes/KOH pH 7.2, 5 mM 
MgCl2, 10% v/v glycerol, 1 mM DTT). Glycerol was used for its protein stabilizing 
effects and magnesium added to importance for GTP/GDP binding although it 
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might be left out at this step. This diluted lysate was dialyzed overnight at 4°C 
against 4 L buffer S.  
The dialyzed solution was filtered through a 0.45 um filter prior to loading on a 
10 mL sulphopropyl (SP)-column (GE Healthcare) equilibrated in buffer S20 
(buffer S with 20 mM KCl). The loaded column was washed in buffer S20 and 
bound protein eluted with a ten column volumes (CV) linear gradient to buffer 
S150 (buffer S with 150 mM KCl). Peak fractions containing eEF2 protein were 
pooled and diluted with four volumes buffer S followed by loading onto a 9 mL 
Source15S column (GE Healthcare) equilibrated in buffer S20. Bound protein 
was eluted with a 24 CV linear gradient to buffer S150. Fractions containing 
eEF2 were pooled and diluted with one volume buffer Q40 (20 mM Tris-HCl pH 
7.6, 5 mM MgCl2, 10% v/v glycerol, 1 mM DTT, 40 mM KCl) and loaded onto a 9 
mL Source15Q column (GE Healthcare) equilibrated in buffer Q40. Unbound 
proteins were washed off with 3 CV buffer Q40 before eluting bound proteins 
with a 9 CV linear gradient to buffer Q275 (as buffer Q40 but with 275 mM KCl). 
Fractions containing eEF2 protein were pooled and concentrated to approx. 5 
mg/mL in a centrifugation concentrator tube with a molecular weight cut-off of 
30000 Da. Concentrated eEF2 protein was centrifuged for ten minutes at 30000 
x g and 4°C before loaded onto a Superdex 200 Increase 10/300 column 
equilibrated in buffer F (20 mM Hepes/KOH pH 7.5, 100 mM KCl, 1 mM DTT). 
Final peak fractions containing eEF2 protein were pooled and the protein 
concentrated to a final concentration of 3.2 mg/mL prior to flash freezing in 
liquid nitrogen and storage at -80°C. Total yield was approximately 4 mg of pure 
eEF2 protein from 60 g cell pellet. For all SDS-PAGE analysis, samples were 
resolved on 4-20% Bis-Tris gels (GenScript) using MOPS running buffer. Gels 
were stained with Instant Blue (Expedeon). 
 
2.3 Western blot analysis 
Purified eEF2 was separated on 12% SDS-PAGE gels. Once separated on the gel, 
protein samples were transferred on a nitrocellulose membrane and then 
blocked for 1 hour using 5% BSA in TBS with 0.5% of Tween 20, shaking at room 
temperature. Diluted anti-eEF2 primary antibody (Santa Cruz, catalogue 
number: sc25634) was added on the membrane and incubated overnight. 
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Secondary antibody (LiCor, catalogue number: 926-32211) was added at room 
temperature.  
2.4 Ribosome Binding 
The activity of eEF2 was asserted based on its ability to bind to the ribosome. 
Human 80S ribosomes were isolated essentially as described in (Khatter et al. 
2014). 80S ribosomes at a final concentration of 5.9 mg/mL were incubated with 
purified eEF2, tRNAPhe in molecular ratios of 1 RS : 5 eEF2 : 2 tRNAPhe in the 
presence of 25 µM fusidic acid and 180 µM GMPPCP. The reaction mixture was 
incubated at 37°C for 10 minutes before loaded onto 5-30% (w/V) sucrose 
gradients. Peak fractions were analysed by SDS-PAGE and blue-staining.  
3. Results and Discussion 
The purification protocol developed here for human eEF2 was adapted from a 
protocol for purification of native yeast eEF2 (René Jørgensen et al. 2002). The 
critical step is the initial capture of eEF2 protein on the SP-sepharose cation 
exchange resin. Despite having a theoretical pI value of 6.41 (ExPASy-
ProtParam), which is below the pH value of buffer S, the protein will bind under 
low-salt conditions. We found that two steps of cation exchange chromatography 
worked the best, with the first step serving to capture the eEF2 protein on the 
SP-sepharose column and the second step on Source15S column to increase 
separation of eEF2 from other bound proteins during gradient elution (Figure 
1A). eEF2 eluted at 55-60 mM salt concentration in cation exchange 
chromatography. 
The following purification step using anion exchange chromatography was 
straightforward as eEF2 readily binds the resin at the pH value of the buffer. We 
found eEF2 protein to elute at 130 mM salt concentration with purity level in the 
peak greatly increased compared to the first step (Fig. 1B). A second anion 
exchange chromatography step using a 1 mL MonoQ column as described in 
(René Jørgensen et al. 2002) was tried but did not result in increased purity so 
was not pursued further (not shown). As a final purification step the eEF2 
protein was subjected to size exclusion chromatography where it eluted with a 
very high purity level (Fig. 1C). The elution volume of the eEF2 peak 
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corresponded to a molecular weight of 94.7 kDa when compared to elution 
volumes of standard globular proteins (Fig. 2). This in turn corresponds well 
with the theoretical molecular weight of 95.3 kDa. In conclusion of purification, 
we found this protocol to work very well in terms of obtaining high purity eEF2 
protein in a monomeric state for use in downstream experiments. The yield of 4 
mg of eEF2 from 60 g of HEK-293F cell pellet compared very well with that 
reported for yeast eEF2, where 10-12 mg per 100 g yeast cells was obtained 
(René Jørgensen et al. 2002). Since the HEK293F cells used for eEF2 isolation 
were a waste product from expression of a secreted protein, this protocol 
describes a rather inexpensive method for obtaining relatively high yields of 
eEF2. Furthermore, this inexpensive source of human cells could possibly be 
used for isolation of other abundant native proteins in a similar manner as long 
as the expressed protein is either tagged or secreted. The purification protocol 
described here for human eEF2 also provides a faster way to obtain eEF2 protein 
as compared to other purification protocols of mammalian eEF2 protein 
(Merrick et al. 1975). 
 
Two different techniques were used to verify that the isolated protein indeed 
was eEF2. First, we checked its reactivity with antibodies that recognized eEF2 
(Liu et al. 2012; Irino et al. 2011). To do this, we loaded increasing amounts of 
purified eEF2 on denaturing gel followed by western blot (Figure 3). As 
expected, using an antibody recognizing eEF2, we identified a band at 95 kDa 
corresponding to the size of eEF2. To complement the western blot verification 
of human eEF2, the protein was analysed by mass spectrometry and positively 
identified as being human eEF2 with a peptide coverage of 90%. Only the His715  
modified with diphtamide was detected in the mass spectrometry analysis, 
showing that all or at least the large majority of the protein is modified (See 
Supplementary Data). This experiment demonstrates that in vivo in human the 
vital diphtamide modification is present in all copies of eEF2. 
 
In order to verify that the purified human eEF2 retained its biochemical 
functionality, we tested the ability of the eEF2 to bind human ribosomes through 
sedimentation in sucrose gradients. Dissociation of eEF2 from the ribosome by 
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turnover of the protein was prevented by the use of a non-hydrolysable GTP 
analogue as well as fusidic acid (Malkin and Lipmann 1969). Analysing the 
protein content in peak fractions from control experiments versus eEF2-
ribosome binding experiments confirmed binding of the purified eEF2 protein to 
the ribosome (Figure 4, gel lane 3). A faint band migrating as the purified eEF2 
was observed in the sedimentation control experiment (Figure 4, gel lane 4). 
This band represents sub-stoichiometric co-purification of human eEF2 with 
human ribosomes as previously observed (Anger et al. 2013). However, in the 
sedimentation experiments with purified eEF2 included, the protein band 
corresponding to eEF2 stained with an intensity comparable to the ribosomal 
proteins bands indicating a close to stoichiometric binding. Thus, although we 
have not tested directly for translocation capability, the purified human eEF2 has 
retained its activity towards ribosome binding. 
4. Conclusions 
In summary, we have purified fully intact and modified eEF2 from native human 
source and characterized it biophysically. The protein elutes as a single well-
shaped peak on size exclusion chromatography indicating that it is correctly 
folded and stable.  The protein was positively identified by western blot analysis 
and mass spectrometry. The purification protocol we have developed allows for 
isolation of highly pure stable and functionally active protein from human cells 
at a reasonably high yield that is suitable for biochemical and structure-function 
studies. 
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Figures 
 
 
 
 
Figure 1. SDS gel analysis of the eEF2 protein at various steps in the purification. 
A) Peak fraction from SourceS purification step. B) Peak fraction from SourceQ 
purification step. C) Peak fraction from Superdex200 Increase gel filtration 
purification step. Mw lane on the left shows molecular weight markers.  
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Figure 2. Gel filtration chromatogram of eEF2 from Superdex 200 Increase. On 
the left is shown the chromatogram with peak elution volume for eEF2 indicated. 
The graph on the right shows the eEF2 elution volume (dashed line) compared to 
calibrated elution volumes.  
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Figure 3. Western blot verification of purified human eEF2 protein. Increasing 
concentrations of purified eEF2 and 80 ug of total HCT116 cell lysate used as 
positive control were run on a 12% SDS-PAGE gel and probed with eEF2 
antibody to confirm the identity of eEF2. Mw, molecular weight marker bands.  
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Figure 4. Ribosome binding activity of native purified human eEF2. Top inserts 
show 5-30% w/V sucrose-density gradient profiles of samples with (left) human 
80S ribosome, human eEF2, tRNAPhe, GMPPCP and fusidic acid and (right) a 
similar experiment with human eEF2 omitted. Peak fractions from density 
gradients were analysed on the SDS gel shown under the profiles. Lane 1; control 
with purified human eEF2, lane 2; molecular weight marker, lane 3; peak fraction 
from sucrose gradient with human eEF2, lane 4; peak fraction from sucrose 
gradient without human eEF2 added. 
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Ribosome binding activity tested and retained 
 
Inexpensive purification from waste-product HEK293F cells 
 
 
